- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05864937
C677T Methylenetetrahydrofolate Reductase Mutation (C677T)
Comparison of Two Preventive Treatments for Patients With Recurrent Miscarriages Carrying a C677T Methylenetetrahydrofolate Reductase Mutation: 5-year Experience
To investigate the effect of anticoagulant treatment on pregnancy outcomes in patients with previous recurrent miscarriages (RM) who carry a methylenetetrahydrofolate reductase (MTHFR) gene mutation.
In this longitudinal retrospective study, patients with RM were treated during pregnancy with either: (i) 100 mg/day aspirin and 5 mg/day folic acid (group 1); or the same protocol plus 0.4 mg/day enoxaparin (group 2). An age-matched group of triparous women without RM or thrombophilia was used as the control group (group 3).
Study Overview
Detailed Description
Recurrent miscarriage (RM) is defined as three or more consecutive spontaneous fetal losses and it affects 0.3% to 1% of pregnancies.To investigate the effect of anticoagulant treatment on pregnancy outcomes in patients with previous recurrent miscarriages (RM) who carry a methylenetetrahydrofolate reductase (MTHFR) gene mutation.
In this longitudinal retrospective study, patients with RM were treated during pregnancy with either: (i) 100 mg/day aspirin and 5 mg/day folic acid (group 1); or the same protocol plus 0.4 mg/day enoxaparin (group 2). An age-matched group of triparous women without RM or thrombophilia was used as the control group (group 3).
Study Type
Enrollment (Actual)
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- patients with three or more consecutive first-trimester miscarriage
- Three or more consecutive first-trimester miscatrriages
- C677T MTHFR gene mutation
Exclusion Criteria:
- Patients with the A1298C polymorphism
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
number of miscarriages
Time Frame: 2years
|
The objective of this study was to evaluate the effect of three components: aspirin, alpha blockers and folic acid in women with miscarriages consecutive first-trimester mutation of the MTHFR C677T gene versus the effet of a combination of aspirin and folic acid in patients with three or more consecutive first-trimester miscarriages who were carrying the C677T MTHFR gene mutation
|
2years
|
Collaborators and Investigators
Investigators
- Principal Investigator: Moncef Ben Khlifa, MD, CHU Amiens
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PI2017_843_0045
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mutation
-
Pamela MunsterNational Cancer Institute (NCI)Not yet recruitingBRCA1 Mutation | BRCA2 Mutation | PALB2 Gene Mutation | ATM Gene Mutation | BRCA Mutation | Checkpoint Kinase 2 Gene MutationUnited States
-
University of California, San FranciscoGlaxoSmithKlineRecruitingMetastatic Solid Tumor | BRCA1 Mutation | BRCA2 Mutation | PALB2 Gene Mutation | ATM Gene MutationUnited States
-
Weill Medical College of Cornell UniversityBasser Research Center for BRCARecruiting
-
University of PennsylvaniaRecruiting
-
Azienda Ospedaliera Universitaria Policlinico Paolo...Unknown
-
Yonsei UniversityMerck KGaA, Darmstadt, GermanyActive, not recruitingPD-L1 Positive Mutation Tumor | EBV Positive Mutation Tumor | MSI-H Mutation Tumor | POLE/POLD1 Mutation TumorKorea, Republic of
-
Marc Dall'Era, MDNational Cancer Institute (NCI); Janssen, LPRecruitingBRCA1 Gene Mutation | BRCA2 Gene Mutation | Prostate Carcinoma | RAD51C Gene Mutation | BRIP1 Gene Mutation | ATM Gene Mutation | CHEK2 Gene Mutation | NBN Gene Mutation | RAD51 Gene Mutation | CDK12 Gene Mutation | CHEK1 Gene Mutation | DNA Damage Response Gene Mutation | DNA Repair Gene Mutation | FANCA Gene Mutation and other conditionsUnited States
-
Sidney Kimmel Comprehensive Cancer Center at Johns...Bristol-Myers Squibb; Vanderbilt University; Avon Breast Health Access FundActive, not recruitingMetastatic Solid Tumor | SF3B1 Gene Mutation | Spliceosome Mutation | U2AF1 Gene Mutation | SRSF2 Gene MutationUnited States
-
Southwest Oncology GroupNational Cancer Institute (NCI)CompletedBRCA1 Gene Mutation | BRCA2 Gene Mutation | Recurrent Squamous Cell Lung Carcinoma | Stage IV Squamous Cell Lung Carcinoma AJCC v7 | BRIP1 Gene Mutation | PALB2 Gene Mutation | ATM Gene Mutation | ATR Gene Mutation | CHEK2 Gene Mutation | NBN Gene Mutation | RAD51 Gene Mutation | CHEK1 Gene Mutation | FANCA Gene... and other conditionsUnited States, Canada
-
Memorial Sloan Kettering Cancer CenterRecruitingBRCA1 Mutation | BRCA2 Mutation | APC Gene Mutation | MLH1 Gene Mutation | RAD51C Gene Mutation | RAD51D Gene Mutation | BRIP1 Gene Mutation | PALB2 Gene Mutation | PTEN Gene Mutation | ATM Gene Mutation | CHEK2 Gene Mutation | BARD1 Gene Mutation | MSH2 Gene Mutation | MSH6 Gene Mutation | PMS2 Gene Mutation | POLD1 Gene... and other conditionsUnited States
Clinical Trials on infertily evaluation
-
IRCCS Eugenio MedeaCompletedIntellectual Disability | Autism Spectrum Disorder | Attention Deficit Hyperactivity DisorderItaly
-
University Hospital, BordeauxRoche Pharma AGRecruitingMultiple Sclerosis, Primary ProgressiveFrance
-
University Hospital, BordeauxRecruitingMultiple SclerosisFrance
-
University Hospital, CaenRecruitingDementia | Alzheimer Disease | Mild Cognitive Impairment | Motoric Cognitive Risk SyndromeFrance
-
University of CatanzaroAzienda Sanitaria Provinciale Di Catanzaro; Azienda Ospedaliera Universitaria...Unknown
-
Ankara Yildirim Beyazıt UniversityCompletedType 2 Diabetes Mellitus | BalanceTurkey
-
Kırıkkale UniversityCompleted
-
Institut National de la Santé Et de la Recherche...Terminated
-
Wake Forest University Health SciencesAgency for Healthcare Research and Quality (AHRQ)Recruiting